Ifp Advisors, Inc Mirati Therapeutics, Inc. Transaction History

Ifp Advisors, Inc

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Jul 30, 2024	SELL	$0.0 - $59.28 $0 - $216,905	-3,659 Reduced 99.48%	19 $0
Q3 2023 Oct 12, 2023	BUY	$27.8 - $45.35 $36,779 - $59,998	1,323 Added 56.18%	3,678 $160,000
Q2 2023 Aug 04, 2023	SELL	$36.13 - $49.49 $5,202 - $7,126	-144 Reduced 5.76%	2,355 $85,000
Q1 2023 Apr 18, 2023	BUY	$36.54 - $54.26 $3,507 - $5,208	96 Added 4.0%	2,499 $92,000
Q4 2022 Feb 07, 2023	BUY	$41.27 - $98.62 $10,606 - $25,345	257 Added 11.98%	2,403 $104,000
Q3 2022 Nov 08, 2022	BUY	$59.5 - $86.7 $8,627 - $12,571	145 Added 7.25%	2,146 $92,000
Q2 2022 Sep 06, 2022	BUY	$39.16 - $88.71 $78,359 - $177,508	2,001 New	2,001 $86,000
Q2 2022 Aug 12, 2022	SELL	$39.16 - $88.71 $78,359 - $177,508	-2,001 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$75.82 - $150.97 $113,350 - $225,700	1,495 Added 295.45%	2,001 $164,000
Q1 2022 Aug 08, 2022	BUY	$75.82 - $150.97 $38,364 - $76,390	506 New	506 $41,000
Q3 2021 Oct 06, 2021	SELL	$132.13 - $177.45 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$144.0 - $179.73 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$158.92 - $221.61 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	BUY	$162.05 - $240.27 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$113.26 - $167.27 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	BUY	$72.01 - $120.39 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$69.78 - $116.21 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	BUY	$70.76 - $128.86 $0 - $0	0 New	0 $0
Q3 2018 Oct 25, 2018	SELL	$47.1 - $62.7 $778,845 - $1.04 Million	-16,536 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$17.2 - $34.95 $284,419 - $577,933	16,536 New	16,536 $0

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.